Scott Gottlieb Acquires 500 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Illumina Stock Performance

Shares of NASDAQ ILMN traded up $5.58 during trading hours on Wednesday, reaching $122.44. The stock had a trading volume of 2,891,643 shares, compared to its average volume of 2,184,935. The firm has a market cap of $18.82 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 2.34 and a beta of 1.40. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.51. The firm has a 50-day moving average of $99.18 and a 200-day moving average of $93.56.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business’s revenue was up .4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

Several hedge funds and other institutional investors have recently bought and sold shares of ILMN. Rise Advisors LLC raised its holdings in Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares during the last quarter. Quent Capital LLC acquired a new position in shares of Illumina in the third quarter worth $29,000. Cullen Frost Bankers Inc. acquired a new position in shares of Illumina in the second quarter worth $41,000. Finally, NewSquare Capital LLC raised its holdings in shares of Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ILMN has been the topic of several analyst reports. Morgan Stanley lifted their target price on Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. TD Cowen lifted their target price on Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a research note on Friday, October 31st. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th. JPMorgan Chase & Co. lifted their target price on Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Finally, Evercore ISI lifted their target price on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average target price of $115.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.